greeksoup/ stock research
Stock research / United States / BCRX / Documents

Biocryst Pharmaceuticals Inc. documents

Biocryst Pharmaceuticals (BCRX) annual report: the 10-K filed 26 February 2026 for the year ended 31 December 2025. Proxy statement (DEF 14A) filed 23 April 2026; latest 10-Q filed 5 August 2026 for the quarter ended 30 June 2026. Each links to the document on EDGAR, with 5 earnings press releases.

Earnings press releases (exhibit 99 to each results 8-K)

FiledDocumentOpenWhere
5 August 2026Results press release, exhibit 99 to the 8-K filed 5 August 2026The releaseEDGAR folder
6 May 2026Results press release, exhibit 99 to the 8-K filed 6 May 2026The releaseEDGAR folder
26 February 2026Results press release, exhibit 99 to the 8-K filed 26 February 2026The releaseEDGAR folder
12 January 2026Results press release, exhibit 99 to the 8-K filed 12 January 2026The releaseEDGAR folder
3 November 2025Results press release, exhibit 99 to the 8-K filed 3 November 2025The releaseEDGAR folder

Annual reports (10-K)

FiledDocumentOpenWhere
26 February 202610-K, period ended 31 December 2025The documentEDGAR folder

Quarterly reports (10-Q)

FiledDocumentOpenWhere
5 August 202610-Q, period ended 30 June 2026The documentEDGAR folder
6 May 202610-Q, period ended 31 March 2026The documentEDGAR folder
4 November 202510-Q, period ended 30 September 2025The documentEDGAR folder

Proxy statements

FiledDocumentOpenWhere
23 April 2026DEF 14A, period ended 11 June 2026The documentEDGAR folder

Annual report to shareholders

FiledDocumentOpenWhere
23 April 2026ARS, period ended 31 December 2025The documentEDGAR folder